Medical and Health Services Listings

The listings compiled within this resource represent a structured reference framework covering substance use disorder treatment facilities, clinical support services, and ancillary health programs operating within the United States. Entries are organized by treatment modality, care level, geographic region, and regulatory status. Understanding what is included, excluded, and unverified in a directory of this scope is essential for any accurate interpretation of the data presented here.

What listings include and exclude

Each listing entry within this directory reflects publicly available facility-level information drawn from federal and state disclosure registries, including the Substance Abuse and Mental Health Services Administration (SAMHSA) National Survey of Substance Abuse Treatment Services (N-SSATS) database. SAMHSA maintains this database as a national registry of facilities that provide substance use disorder treatment, and listings that appear here correspond to facility types recognized under that framework.

Inclusions span four primary service categories:

1. Residential treatment facilities (short-term and long-term), including those classified under American Society of Addiction Medicine (ASAM) Levels of Care
2. Outpatient and intensive outpatient programs licensed by state behavioral health authorities
3. Opioid Treatment Programs (OTPs) federally certified under 42 CFR Part 8, administered by SAMHSA's Center for Substance Abuse Treatment (CSAT)
4. Hospital-based detoxification and inpatient rehab medical services operating under Medicare Conditions of Participation (42 CFR Part 482)

Exclusions are equally specific. Peer support groups, informal recovery housing without state licensure, faith-community programs that do not hold a behavioral health facility license, and private practitioners operating outside a licensed treatment facility are not indexed here. Listings do not include general-practice physicians who prescribe buprenorphine under the Drug Addiction Treatment Act of 2000 (DATA 2000) unless they operate within a formally licensed outpatient treatment program.

Verification status

Verification status is assigned at the listing level based on the documentation tier the facility has satisfied. Three tiers apply:

• Accreditation-confirmed: The facility holds active accreditation from The Joint Commission (TJC) or the Commission on Accreditation of Rehabilitation Facilities (CARF). Accreditation status is cross-referenced against each body's public verification tools. Details on what these credentials require are covered under Joint Commission and CARF accreditation standards.
• State-licensed only: The facility holds a current state behavioral health license but has not pursued or maintained national accreditation. State licensing standards vary across all 50 jurisdictions; requirements under, for example, California's Department of Health Care Services differ from those enforced by the Texas Health and Human Services Commission.
• SAMHSA-listed, unverified: The facility appears in the SAMHSA N-SSATS data but independent confirmation of current licensure or accreditation has not been obtained for this directory cycle. Listings in this category carry an explicit unverified notation.

For SAMHSA-certified treatment programs, OTP certification status is a federally regulated designation, not a voluntary credential. Any OTP dispensing methadone for opioid use disorder must maintain this certification under federal law; facilities that lose certification must cease dispensing within the terms set by CSAT.

Coverage gaps

No national directory of substance use treatment services achieves complete coverage, and this resource is no exception. Structural gaps exist for identifiable reasons:

Geographic underrepresentation is concentrated in rural counties. The Health Resources and Services Administration (HRSA) designates Health Professional Shortage Areas (HPSAs); as of the most recent HRSA data cycle, more than 60% of designated mental health HPSAs are located in non-metropolitan areas. Facilities in these zones are less likely to appear in commercial or federated databases.

Specialty population programs — including adolescent drug rehab programs, women-specific drug rehab, and veterans drug rehab programs — are listed where facility-level data confirms the specialty designation. Programs that serve these populations without a formal licensing or accreditation designation for the specialty may not be captured.

Telehealth-delivered services present a classification challenge. The expansion of remote prescribing authority for buprenorphine under the DEA's 2023 telemedicine rulemaking framework (see 21 CFR Part 1306) created a category of providers who deliver treatment entirely outside a licensed facility structure. These providers appear in listings only where they operate under or in conjunction with a licensed clinic or OTP.

Sliding-scale and publicly funded programs are frequently underrepresented in directories that rely on facility self-reporting. State-funded drug rehab programs often operate through county behavioral health departments rather than as freestanding licensed entities, which limits their indexability.

Listing categories

Listings are organized into six functional categories aligned with standard clinical and regulatory classifications:

1. Detoxification services — medically managed and clinically managed withdrawal, corresponding to ASAM Level 3.7 and 4.0 designations. See detox services in drug rehab for clinical definitions.
2. Residential treatment — inclusive of 28-day short-term and long-term residential programs exceeding 30 days, classified under ASAM Levels 3.1 through 3.5.
3. Partial Hospitalization Programs (PHPs) — structured day treatment at ASAM Level 2.5; covered in detail under partial hospitalization programs.
4. Outpatient treatment — standard outpatient (fewer than 9 hours of structured service per week) and intensive outpatient (9 or more hours per week), per ASAM Level 1 and 2.1 criteria.
5. Medication-Assisted Treatment (MAT) providers — includes methadone treatment clinics, buprenorphine and Suboxone treatment programs, and naltrexone and Vivitrol programs, each governed by distinct federal regulatory frameworks.
6. Co-occurring disorder programs — facilities holding a dual-diagnosis designation under state licensing criteria and addressing co-occurring mental health and substance use disorders within a single treatment episode.